Inventiva Past Earnings Performance
Past criteria checks 0/6
Inventiva's earnings have been declining at an average annual rate of -17.7%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 7.2% per year.
Key information
-17.7%
Earnings growth rate
3.5%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 7.2% |
Return on equity | -119.3% |
Net Margin | -288.5% |
Next Earnings Update | 28 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Inventiva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 19 | -54 | 15 | 57 |
30 Sep 22 | 14 | -55 | 13 | 57 |
30 Jun 22 | 10 | -56 | 12 | 56 |
31 Mar 22 | 10 | -56 | 11 | 53 |
31 Dec 21 | 9 | -50 | 11 | 45 |
30 Sep 21 | 7 | -45 | 10 | 36 |
30 Jun 21 | 6 | -41 | 10 | 26 |
31 Mar 21 | 5 | -36 | 9 | 22 |
31 Dec 20 | 5 | -34 | 8 | 21 |
30 Sep 20 | 7 | -29 | 7 | 23 |
30 Jun 20 | 10 | -25 | 6 | 26 |
31 Mar 20 | 10 | -27 | 6 | 28 |
31 Dec 19 | 11 | -30 | 6 | 32 |
30 Sep 19 | 9 | -34 | 6 | 32 |
30 Jun 19 | 7 | -37 | 6 | 31 |
31 Mar 19 | 8 | -35 | 6 | 30 |
31 Dec 18 | 7 | -33 | 6 | 29 |
30 Sep 18 | 8 | -29 | 6 | 29 |
30 Jun 18 | 9 | -25 | 6 | 28 |
31 Mar 18 | 9 | -22 | 6 | 27 |
31 Dec 17 | 10 | -19 | 5 | 26 |
30 Sep 17 | 11 | -16 | 5 | 25 |
30 Jun 17 | 13 | -13 | 5 | 24 |
31 Mar 17 | 14 | -10 | 5 | 22 |
31 Dec 16 | 14 | -7 | 4 | 21 |
30 Sep 16 | 13 | -8 | 4 | 20 |
30 Jun 16 | 12 | -8 | 4 | 20 |
31 Mar 16 | 10 | -9 | 4 | 19 |
31 Dec 15 | 9 | -9 | 4 | 18 |
31 Dec 14 | 6 | -7 | 4 | 15 |
31 Dec 13 | 5 | -7 | 4 | 12 |
Quality Earnings: IVAP is currently unprofitable.
Growing Profit Margin: IVAP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IVAP is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.
Accelerating Growth: Unable to compare IVAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVAP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: IVAP has a negative Return on Equity (-119.35%), as it is currently unprofitable.